Eli Lilly Says FDA Approves Trijardy for Patients With Type 2 Diabetes

Date : 01/27/2020 @ 11:31PM
Source : Dow Jones News
Stock : Eli Lilly and Co (LLY)
Quote : 126.13  -3.06 (-2.37%) @ 1:00AM
After Hours
Last Trade
Last $ 127.98 ▲ 1.85 (1.47%)

Eli Lilly Says FDA Approves Trijardy for Patients With Type 2 Diabetes

Eli Lilly (NYSE:LLY)
Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more Eli Lilly Charts.
   By Stephen Nakrosis 

Eli Lilly and Co. (LLY) said Monday the U.S. Food and Drug Administration approved Trijardy to lower blood sugar in adults with type 2 diabetes.

Lilly said Trijardy XR, which is marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly, combines three medicines--Jardiance, or empagliflozin, Tradjenta, or linagliptin, and metformin hydrochloride extended release--in one pill.

Trijardy is indicated for use along with diet and exercise to lower blood sugar.

Trijardy is a once-a-day medication, Lilly said, adding it will be available in four different dosages.


--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

January 27, 2020 18:16 ET (23:16 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest LLY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.